Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients Akebia Therapeutics, Inc., a pharmaceutical development and discovery company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease . AKB-6548 can be an orally bioavailable hypoxia-inducible factor-prolyl hydroxylase inhibitor designed to increase the natural creation of erythropoietin and cause a controlled, gradual rise in hemoglobin in patients with anemia suhagra.org . The analysis met its primary endpoint of a dose-responsive increase in hemoglobin from baseline over the 42 days of the study .
In the airways, bitter substances both activate the receptors and elicit a response – – the increased beating of the cilia – – made to get rid of the offending material. Shah and co-first author Yehuda Ben-Shahar, Ph.D., an assistant professor of biology at Washington University who was simply a postdoctoral fellow at the UI when the study was conducted, worked in the laboratory of senior study writer Michael Welsh, M.D., UI professor of internal medication and molecular biophysics and physiology, who holds the Roy J. Carver Chair of Internal Medicine and Physiology and Biophysics. Welsh also is a Howard Hughes Medical Institute investigator. These findings claim that we have evolved advanced mechanisms to protect ourselves from harmful environmental stimuli, Ben-Shahar stated. Our work also suggests that shedding cilia in the lung area, due to disease or smoking, would result in a reduced general ability to detect harmful inhaled chemicals, increasing the likelihood of further damaging an hurt lung.